Clinical trials: Lymphocytic Leukemia
Leukemia, Lymphoma
Everolimus in Treating Patients With Lymphoma That Has Relapsed or Not Responded to Previous Treatment
RATIONALE: Everolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer.
- Conditions
- Leukemia, Lymphoma, Lymphoproliferative Disorder
- Trial name
- NCT00436618
- Testing
- Everolimus
- Where
- 3 sites in United States
- Volunteers
- 277 people
- Sponsor
- Mayo Clinic
Acute Adult T-Cell Leukemia/Lymphoma, Adult T-Cell Leukemia/Lymphoma
Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma
This phase II trial studies how well nivolumab works in treating patients with human T-cell leukemia virus (HTLV)-associated T-cell leukemia/lymphoma.
- Conditions
- Acute Adult T-Cell Leukemia/Lymphoma, Adult T-Cell Leukemia/Lymphoma, Chronic Adult T-Cell Leukemia/Lymphoma, HTLV-1 Infection
- Trial name
- NCT02631746
- Testing
- Laboratory Biomarker Analysis, Nivolumab, Pharmacogenomic Study
- Where
- 6 sites in United States
- Volunteers
- 3 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia, Lymphoma
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant
RATIONALE: Giving chemotherapy, such as busulfan and fludarabine phosphate, before a peripheral blood stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT01118013
- Testing
- anti-thymocyte globulin, donor lymphocytes, filgrastim
- Where
- 10 sites in United States
- Volunteers
- 6 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Mantle Cell Lymphoma, Diffuse Large Cell Lymphoma
Study of Infusion of Blood Cells (Lymphocytes) to Stimulate the Immune System to Fight Leukemia/Lymphoma
The study of whether an infusion of blood cells called lymphocytes from a donor can stimulate the immune system to fight your leukemia/lymphoma.
- Conditions
- Mantle Cell Lymphoma, Diffuse Large Cell Lymphoma, Burkitts Lymphoma, T Cell Lymphomas
- Trial name
- 273 (NCT01685606)
- Testing
- cellular immunotherapy
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Brown University
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia in Remission
Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies
This pilot clinical trial studies the side effects of irradiated donor cells following stem cell transplant in controlling cancer in patients with hematologic malignancies.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia in Remission, Hematopoietic Cell Transplantation Recipient, JAK2 Gene Mutation
- Trial name
- NCT03272633
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Irradiated Allogeneic Cells
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Rutgers, The State University of New Jersey
Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia
Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer
This clinical trial studies the side effects and best dose of giving fludarabine and total-body irradiation (TBI) together followed by a donor stem cell transplant and cyclosporine and mycophenolate mofetil in treating human…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission
- Trial name
- NCT00112593
- Testing
- fludarabine phosphate, total-body irradiation, peripheral blood stem cell transplantation
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Fred Hutchinson Cancer Center
Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia
Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia
This phase I/II trial studies the side effects and the best dose of ofatumumab and dinaciclib and to see how well they work in treating patients with relapsed or refractory chronic lymphocytic leukemia, small lymphocytic…
- Conditions
- Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia
- Trial name
- NCT01515176
- Testing
- Dinaciclib, Laboratory Biomarker Analysis, Ofatumumab
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML
This phase I/II trial studies the side effects and best dose of bosutinib when given together with inotuzumab ozogamicin and to see how well it works in treating patients with acute lymphoblastic leukemia or chronic myeloid…
- Conditions
- B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Blasts More Than 5 Percent of Bone Marrow Nucleated Cells, CD22 Positive
- Trial name
- NCT02311998
- Testing
- Bosutinib, Inotuzumab Ozogamicin
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- M.D. Anderson Cancer Center
Chronic Lymphocytic Leukemia, Leukemia
Identifying Prognostic Factors in Frontline FCR for Patients With Chronic Lymphocytic Leukemia (CLL)
The goal of this clinical research study is to learn more about the characteristics of CLL, including genes and chromosome abnormalities and proteins expressed by the leukemia cells, which may help doctors predict if patients who…
- Trial name
- NCT00759798
- Testing
- Fludarabine, Cyclophosphamide, Rituximab
- Where
- United States
- Volunteers
- 289 people
- Sponsor
- M.D. Anderson Cancer Center
Blast Phase Philadelphia Chromosomes Positive (Ph+) Chronic Myelogenous Leukemia (CML), Philadelphia Chromosome Positive (Ph+) Acute Lymphocytic Leukemia (ALL)
Growth Factor Signature (GFS) Pilot Study (MK0000-098)(COMPLETED)
This study will evaluate a gene expression signature (Growth Factor Signature [GFS]) as a biomarker for response/resistance to BRC-ABL oncogene inhibitors.
- Trial name
- NCT00860535
- Testing
- Comparator: Biomarker evaluation
- Volunteers
- 9 people
- Sponsor
- Merck Sharp & Dohme LLC
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation
The purpose of this phase I/II study is to define the maximum tolerated dose of 5-AzaC and the effect on grade II-IV GvHD when given after matched unrelated donor transplant (MUD).
- Conditions
- Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Trial name
- NCT01747499
- Testing
- Azacitidine
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Washington University School of Medicine
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma
Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma
This phase II clinical trial studies how well Akt inhibitor MK2206 works in treating patients with relapsed lymphoma. Akt inhibitor MK2206 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, B-cell Adult Acute Lymphoblastic Leukemia
- Trial name
- NCT01258998
- Testing
- Akt inhibitor MK2206, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Myelodysplastic Syndromes, Acute Myeloid Leukemia
Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab
This is a single arm, open-label, Phase 1b study of pembrolizumab for patients with myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL) whose disease has relapsed after receiving…
- Conditions
- Myelodysplastic Syndromes, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
- Trial name
- NCT03286114
- Testing
- Pembrolizumab
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Michigan Rogel Cancer Center
Lymphoma, Leukemia
Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies
Primary objective: To determine the safety of adback T- or Natural Killer (NK) cells in patients with lymphoid malignancies receiving allogeneic stem cell transplantation with Campath-IH containing conditioning regimen.
- Trial name
- NCT00536978
- Testing
- ARA-C, BCNU, Campath-1H
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- M.D. Anderson Cancer Center
Lymphoma, Non-Hodgkin; Leukemia, Chronic Lymphocytic
A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's Lymphoma
This is a Phase 1 dose-exploration study of LAM-002A administered by mouth in patients with relapsed or refractory B-cell NHL. Safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD),and preliminary anti-tumor activity…
- Trial name
- LAM-002A/NHL (NCT02594384)
- Testing
- LAM-002A, Rituximab, Atezolizumab
- Where
- 11 sites in United States
- Volunteers
- 62 people
- Sponsor
- IRulya Therapeutics Inc.
Acute Lymphoblastic Leukemia
Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)
The purpose of this study is to confirm whether the bispecific T cell engager antibody blinatumomab (MT103) is effective and safe in the treatment of patients with relapsed or refractory Acute Lymphoblastic Leukemia (ALL).
- Trial name
- NCT01466179
- Testing
- Blinatumomab
- Where
- 39 sites in United States, France and 4 more
- Volunteers
- 225 people
- Sponsor
- Amgen Research (Munich) GmbH
Non Hodgkin Lymphoma
An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma
This is a Phase I, open-label, multicenter study of HMPL-523 administered orally to patients with relapsed or refractory lymphoma who have exhausted approved therapy options.
- Trial name
- NCT03779113
- Testing
- HMPL-523
- Where
- 32 sites in United States, Denmark and 5 more
- Volunteers
- 69 people
- Sponsor
- Hutchmed
Leukaemia, Lymphocytic, Chronic
Ofatumumab + Chlorambucil vs Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia
The purpose of this study was to evaluate the safety and efficacy of ofatumumab added to chlorambucil in patients with untreated Chronic Lymphocytic Leukemia.
- Trial name
- COMPLEMENT 1 (NCT00748189)
- Testing
- chlorambucil, tablets, ofatumumab (GSK1841157) infusion
- Where
- 154 sites in United States, Belgium and 15 more
- Volunteers
- 447 people
- Sponsor
- Novartis Pharmaceuticals
Leukemia, Myeloid, Chronic, Anemia, Aplastic
Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor
The purpose of this study is to determine whether the addition of parathyroid hormone after a sequential cord blood transplant will improve engraftment, which is the ability of the transplanted stem cells to grow and to…
- Conditions
- Leukemia, Myeloid, Chronic, Anemia, Aplastic, Myelofibrosis, Lymphoma
- Trial name
- NCT00393380
- Testing
- Parathyroid Hormone (teriparatide)
- Where
- 4 sites in United States
- Volunteers
- 13 people
- Sponsor
- The Emmes Company, LLC
Leukemia, Myeloid, Chronic, Lymphomas
Post Transplant Donor Lymphocyte Infusion
The purpose of this study is to test the hypothesis that a pre-infusion preparative regimen of cyclophosphamide and fludarabine will improve the effectiveness of DLI in patients with blood cancers.
- Conditions
- Leukemia, Myeloid, Chronic, Lymphomas, Multiple Myeloma, Myelodysplastic Syndrome
- Trial name
- NCT00167180
- Testing
- Donor Lymphocyte Infusion, Induction Chemotherapy
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Masonic Cancer Center, University of Minnesota